NewAmsterdam Pharma Beats Q3 2026 Estimates as Revenue Rises 5407% to $19.2M

NewAmsterdam Pharma (NAMSW) beat estimates for the third quarter of 2026 on both revenue and EPS. Revenue was $19.2 million, up 5407% from a year earlier, above the $8.8 million estimate, and EPS was -$0.14, up 77% from a year earlier, above the -$0.47 estimate.

Q3 2026 scorecard

By our calculation, revenue was $10.3 million above the estimate and EPS was $0.33 above it. The QoQ column compares with the previous quarter's revenue of $3.7 million and EPS of -$0.52. The YoY column compares with $348 thousand and -$0.61 in the same quarter a year earlier.

GAAP results

• Net loss. The company reported a net loss of $17.4 million on a GAAP basis, compared with a net loss of $72.0 million a year earlier.

Track record

• EPS record. EPS beat the estimate in 4 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 6 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $348 thousand, $32 thousand, $3.0 million, $3.7 million and $19.2 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$0.45 and revenue of $15.8 million next quarter, based on 1 analyst.
• Next report. NewAmsterdam Pharma is next expected to report on March 3, 2027.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 5407% increase to $19.2 million.
• Related coverage. See our reports on Advanced Drainage Systems, Americold Realty Trust, Agios Pharmaceuticals and NCR Voyix.

Sources: Results are from NewAmsterdam Pharma's Nov. 4, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from NewAmsterdam Pharma's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.